RadNet to participate in study evaluating Alzheimer's therapy

07/17/2013 | AuntMinnie.com (free registration)

RadNet announced its participation in a clinical trial to evaluate Eisai's investigational drug E2609, a beta-site amyloid precursor protein-cleaving enzyme inhibitor, for the treatment of Alzheimer's disease. RadNet facilities in Los Angeles and Baltimore will supply the PET/CT equipment for the trial, and GE Healthcare's F-18 flutemetamol investigational PET agent will be used to determine which patients may participate in the Phase I trial.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care